冠状动脉内注射替奈普酶预防回声衰减斑块患者PCI相关心肌梗死:多中心前瞻性随机对照试验研究方案
本研究为多中心前瞻性随机对照试验,旨在评估在血管内超声检测到回声衰减斑块的患者中,PCI术前冠状动脉内低剂量替奈普酶能否降低PCI相关心肌梗死发生率并改善临床结局。主要结局为PCI后48小时内PCI相关心肌梗死发生率,次要结局包括术后高敏肌钙蛋白I超过正常基线5、10、35、70倍的患者比例、支架植入及后扩张后冠脉慢血流与帧数、住院及1个月随访期间MACE发生率,随访1个月。
要点
- 在IVUS检测到回声衰减斑块的患者中,PCI术前冠脉内低剂量替奈普酶可能降低PCI相关心肌梗死发生率。
- 主要结局为PCI后48小时内PCI相关心肌梗死发生率。
- 试验为多中心前瞻性随机对照试验,随访1个月,注册号ChiCTR2400084840,注册日期2024年5月27日。
核心结论
- 该试验可能证明PCI后立即冠状动脉内给予低剂量替奈普酶可有效降低回声衰减斑块患者的PCI相关心肌梗死发生率,同时确认该治疗方式的安全性。
研究设计与样本
- 多中心、前瞻性随机对照试验,随访1个月,注册于中国临床试验注册中心(ChiCTR2400084840),注册日期2024年5月27日。
关键数值与推荐
- 主要结局为PCI后48小时内PCI相关心肌梗死发生率,作为评估替奈普酶PCI预防回声衰减斑块患者未来主要不良心血管事件(MACE)疗效的有效替代终点(Bulluck等,Eur Heart J 42:2630-42, 2021){1b.1}。
- 次要结局包括术后高敏肌钙蛋白I超过正常基线5、10、35、70倍的患者比例。
- 次要结局包括支架植入及后扩张后冠脉慢血流发生率和血管造影血流帧数。
- 次要结局包括住院期间及1个月随访期间MACE发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous coronary intervention (PCI)-related myocardial infarction (MI), especially the distal type associated with microvascular dysfunction, is not an uncommon complication of the procedure. Specific lesion features, the echo-attenuated plaques (EA) in particular, are well-established contributors to the pathogenesis of distal-type MI. These plaques are prone to disruption during PCI, leading to microvascular thrombosis and distal embolism. Tenecteplase (TNK), a 3rd-generation thrombolytic drug, has demonstrated effective thrombolytic capacity without significantly increasing the bleeding risk. Our study aims to evaluate whether a low-dose intracoronary TNK administration prior to PCI in patients with intravascular ultrasound (IVUS)-detected EA can reduce the occurrence of PCI-related MI and improve clinical outcomes. METHODS: This trial is designed as a multicenter, prospective randomized controlled trial with a 1-month follow-up. The primary outcome of the study is the incidence of PCI-related myocardial infarction (MI) occurring within 48 h after PCI, which serves as a valid surrogate endpoint for assessing the efficacy of tenecteplase-based PCI in preventing future major adverse cardiovascular events (MACE) in patients with EA (Bulluck, et. al, Eur Heart J 42:2630-42, 2021) {1b.1}. Secondary outcomes include the proportion of patients with elevated postoperative high-sensitivity cTnI exceeding 5, 10, 35, and 70 times of the normal baseline, incidence of coronary slow flow after stent implantation and post-dilation, frame count of angiographic flow after stent implantation and post-dilation, as well as the incidence of MACE during hospitalization and at the 1-month follow-up. DISCUSSION: This trial may demonstrate that an immediate intracoronary administration of low-dose TNK following PCI can effectively lower the incidence of PMI in patients with EA, while confirming the safety of this therapeutic approach. TRIAL REGISTRATION: Chinese Clinical Trial Registry ( ChiCTR2400084840 ). Registered on May 27, 2024.
引用
- Hong XL, Loh YH, Li DB, et al. Intracoronary administration of tenecteplase to prevent PCI-related myocardial infarction in patients with echo-attenuated coronary plaques: study protocol for a multicenter, prospective, randomized controlled trial. Trials. 2024. PMID: 39587685. doi:10.1186/s13063-024-08605-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。